Moreover, we cannot exclude the possibility of efficacy of an anti-IL-5/IL-5R treatment also in patients with extra-pulmonary involvement, considering that eosinophils play a central pathogenetic role in the organ injury occurring in EGPA. The gene discussed is IL5RA; the disease is eosinophilic granulomatosis with polyangiitis.